Fedratinib

Overview

Fedratinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1287853).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Fedratinib expires 23 Sept 2039 and exclusivity 15 Aug 2026. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide

Canonical SMILES

CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4

InChIKey

JOOXLOJCABQBSG-UHFFFAOYSA-N